Question 1

What is the ESG rating for BMY?

Accepted Answer

Bristol-Myers Squibb Company has the following ESG ratings: MSCI ESG Rating: 75.4.

Question 2

What are the main strengths of investing in BMY?

Accepted Answer

The main strengths of investing in Bristol-Myers Squibb Company include: Science-based emissions targets with 100% renewable electricity goal by 2030, Growth Portfolio revenue up 16% offsetting patent cliff impacts, $1 billion diverse supplier commitment demonstrating social equity leadership.

Question 3

What are the potential drawbacks of investing in BMY?

Accepted Answer

Potential drawbacks of investing in Bristol-Myers Squibb Company include: Eliquis patent expiry by 2028 threatens 30%+ of current revenues, Medicare price negotiations creating revenue pressure starting 2026, Medium ESG risk rating reflects governance challenges around drug pricing.

Question 4

What are the key financial metrics for BMY?

Accepted Answer

Key financial metrics for Bristol-Myers Squibb Company include: Market Cap: $3.56 billion, Current Price: $117.20, Dividend Yield: 3.68%.

Bristol-Myers Squibb Company

Detailed View

BMY

ESG Ratings